share_log

Oppenheimer Upgrades Ventyx Biosciences to Outperform, Announces $12 Price Target

Benzinga ·  Mar 12 04:56

Oppenheimer analyst Jeff Jones upgrades Ventyx Biosciences (NASDAQ:VTYX) from Perform to Outperform and announces $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment